Sign in
VKTX Stock Price, Chart, Stats & News
Viking Therapeutics, Inc.
Save
4.42B
Market cap
–
Current P/E
–
Forward P/E
VKTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -50.25% |
ROE | -48.04% |
D/E | 0.00x |
Interest coverage ratio | -7023.96x |
VKTX valuation
P/E | – |
P/S | – |
P/B | 5.80x |
P/CF | -13.30x |
P/FCF | -13.48x |
P/OCF | -13.30x |
PEG | 0.21x |
EV multiple | -9.98x |
About
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD).
Similar securities
Based on sector and market capitalization
Report issue